ASTHALIN Inhaler (Salbutamol sulphate)
Table of Content
Each actuation delivers:
Salbutamol Sulphate IP equivalent to Salbutamol IP …….100 mcg
Suspended in propellant 134a…………q.s.
Salbutamol is a selective beta2-adrenoreceptor agonist. At therapeutic doses, it acts on the beta2-adrenoceptors of bronchial smooth muscle, with little or no action on the beta1-adrenoceptors of the cardiac muscle. Salbutamol provides short-acting (4-6 hours) bronchodilation with a fast onset (within 5 minutes) in reversible airways obstruction.
Salbutamol administered intravenously has a half-life of 4-6 hours and is cleared partly renally and partly by metabolism to the inactive 4'-O-sulphate (phenolic sulphate), which is also excreted primarily in the urine. The faeces are a minor route of excretion.
After administration by the inhaled route, between 10% and 20% of the dose reaches the lower airways. The remainder is retained in the delivery system or is deposited in the oropharynx from where it is swallowed. The fraction deposited in the airways is absorbed into the pulmonary tissues and circulation, but is not metabolized by the lungs. On reaching the systemic circulation, it becomes accessible to hepatic metabolism and is excreted, primarily in the urine, as unchanged drug and as phenolic sulphate.
The swallowed portion of an inhaled dose is absorbed from the gastrointestinal tract and undergoes considerable first-pass metabolism to phenolic sulphate. Both unchanged drug and conjugate are excreted primarily in the urine. Most of a dose of salbutamol given intravenously, orally, or by inhalation is excreted within 72 hours. Salbutamol is bound to plasma proteins to the extent of 10%.
ASTHALIN Inhaler is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.
ASTHALIN Inhaler is indicated for the prevention of exercise induced bronchospasm in patients 4 years of age and older.
Administer ASTHALIN Inhaler by oral inhalation only.
Adults (Including the Elderly)
For relief of acute episodes of bronchospasm:
1 or 2 puffs as necessary repeated every 4 to 6 hours. In some patients, 1 inhalation every 4 hours may be sufficient. More frequent administration or a greater number of inhalations is not recommended.
To prevent allergen- or exercise-induced bronchospasm:
Two inhalations, 15 to 30 minutes prior to exercise or exposure to allergen.
For chronic therapy, two puffs up to four times a day.
The maximum dose up to 800 mcg in 24 hours.
For relief of acute episodes of bronchospasm:
The usual dosage for children under the age of 12 years: one puff (100 micrograms) - The dose may be increased to two puffs if required.
To prevent allergen- or exercise-induced bronchospasm:
1-2 puffs, 15 to 30 minutes prior to exercise or exposure to allergen
The usual dosage for children under the age of 12 years: up to two puffs 4 times daily.
The maximum dose up to 800 mcg in 24 hours.
ASTHALIN Inhaler may be used with a Zerostat/Zerostat VT Spacer device by patients who find it difficult to synchronize aerosol actuation with inspiration of breath.
Hypersensitivity to Any of the Components
- Rare cases of hypersensitivity reactions including urticaria, angioedema and rash have been reported after the use of salbutamol.
- Although intravenous salbutamol, and occasionally salbutamol tablets, are used in the management of premature labour uncomplicated by conditions such as placenta praevia, ante-partum haemorrhage, or toxaemia of pregnancy, inhaled salbutamol preparations are not appropriate for managing premature labour. Salbutamol preparations should not be used for threatened abortion.
Inhaled salbutamol sulphate can produce paradoxical bronchospasm, which may be life-threatening. If paradoxical bronchospasm occurs, ASTHALIN Inhaler should be discontinued immediately and alternative therapy instituted. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister.
Salbutamol, like all other beta2-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of salbutamol at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, salbutamol, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
Deterioration of Asthma
Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of ASTHALIN Inhaler than usual, this may be a marker of destabilization of asthma and requires re-evaluation of the patient and treatment regimen, with special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.
Use of Anti-Inflammatory Agents
The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids, to the therapeutic regimen.
Immediate Hypersensitivity Reactions
Immediate hypersensitivity reactions may occur after administration of salbutamol sulphate inhalation aerosol, as demonstrated by cases of urticaria, angio-oedema, rash, bronchospasm, hypotension, and anaphylaxis. Discontinue ASTHALIN Inhaler if immediate hypersensitivity reactions occur.
Do Not Exceed Recommended Dose
Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. The exact cause of death is unknown, but cardiac arrest following an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected.
Salbutamol, like other sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus and in patients who are unusually responsive to sympathomimetic amines. Salbutamol should be administered cautiously to patients with thyrotoxicosis. Large doses of intravenous salbutamol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.
As with other beta-agonists, salbutamol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation.
Other short-acting sympathomimetic aerosol bronchodilators should not be used concomitantly with salbutamol. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.
Beta-Adrenergic Receptor Blocking Agents
Beta-blockers not only block the pulmonary effect of beta-agonists, such as ASTHALIN Inhaler, but may also produce severe bronchospasm in patients with asthma. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to use beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers should be considered, although they should be administered with caution.
The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical relevance of these effects is not known, caution is advised in the coadministration of ASTHALIN Inhaler with non-potassium-sparing diuretics. Consider monitoring potassium levels.
Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids, digoxin, diuretics, and by hypoxia. It is recommended that serum potassium levels be monitored in such situations.
Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after single dose intravenous and oral administration of salbutamol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical relevance of these findings for patients with obstructive airway disease who are receiving inhaled salbutamol and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and salbutamol.
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants
ASTHALIN Inhaler should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants or within 2 weeks of discontinuation of such agents, because the action of salbutamol on the vascular system may be potentiated.
Pregnancy Category C
Administration of ASTHALIN Inhaler during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus. As with the majority of drugs, there is little published evidence of the safety of salbutamol in the early stages of human pregnancy, but in animal studies there was evidence of some harmful effects on the fetus at very high dose levels.
There are no well-controlled human trials that have investigated effects of salbutamol on preterm labor or labor at term. Because of the potential for beta-agonist interference with uterine contractility, use of ASTHALIN Inhaler during labor should be restricted to those patients in whom the benefits clearly outweigh the risk.
As salbutamol is probably secreted in breast milk, its use in nursing mothers requires careful consideration. It is not known whether salbutamol has a harmful effect on the neonate, and so its use should be restricted to situations where it is felt that the expected benefit to the mother is likely to outweigh any potential risk to the neonate.
Results from the 2-week pediatric clinical study in patients with asthma 4 to 11 years of age showed that the adverse reaction profile was similar to that of the adolescent and adult population. These adverse reactions included upper respiratory tract infection, nasopharyngitis, pyrexia and tachycardia. The safety and effectiveness of ASTHALIN Inhaler in children under 4 years of age has not been established.
Clinical trials of salbutamol did not include sufficient numbers of subjects aged 65 years and older to determine whether older subjects respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Use of ASTHALIN Inhaler may be associated with paradoxical bronchospasm, cardiovascular effects, immediate hypersensitivity reactions and hypokalemia. Other rare undesirable effects included hypotension and collapse, mouth and throat irritation, muscle cramps and peripheral vasodilatation. Myocardial infarction was reported as an unknown undesirable effect with salbutamol. Common side- effects with ASTHALIN Inhaler included tremor and headache.
Clinical Trials Experience
Adults and Adolescents 12 Years of Age and Older
The two 12-week, randomized, double blind studies in 610 adolescent and adult patients with asthma that compared salbutamol HFA (n=202), a CFC 11/12-propelled salbutamol inhaler (n=207), and an HFA-134a placebo inhaler (n=201). Overall, the incidence and nature of undesirable effects for salbutamol HFA and the HFA-134a was comparable. Adverse reactions that occurred at a rate of 3% or greater in group treated with salbutamol HFA and more frequently in the group treated with salbutamol HFA than in HFA-134a placebo were: showed common (3% or greater reported) adverse reactions – ear, nose and throat irritation, lower respiratory, upper respiratory inflammation, viral respiratory infections, cough and musculoskeletal pain.
Adverse reactions reported by less than 3% of the adolescents and adult patients receiving salbutamol HFA and by a greater proportion of subjects receiving salbutamol HFA than HFA-134a placebo inhaler and that have the potential to be related to salbutamol HFA include diarrhea, laryngitis, oropharyngeal edema, cough, lung disorders, tachycardia, extrasystoles, palpitation and dizziness.
Paradoxical bronchospasm, hoarseness, arrhythmias (including atrial fibrillation, supraventricular tachycardia and extrasystoles), and hypersensitivity reactions (including urticaria, angioedema, rash) have been reported.
In addition, salbutamol like other sympathomimetic agents, can cause adverse reactions such as hypokalemia, hypertension, peripheral vasodilation, angina, tremor, central nervous system stimulation, hyperactivity, sleeplessness, headache, muscle cramps, drying or irritation of the oropharynx, and metabolic acidosis.
If you experience any side-effects, talk to your doctor or pharmacist or write to firstname.lastname@example.org. You can also report side effects directly via the national pharmacovigilance program of India by calling on 1800 180 3024.
By reporting side-effects, you can help provide more information on the safety of this product.
The expected signs and symptoms of overdosage are those of excessive beta-adrenergic stimulation, and/or occurrence or exaggeration of any of the signs and symptoms of beta-adrenergic stimulation viz., seizures, angina, hypertension or hypotension, tachycardia (with rates up to 200 beats/min), arrhythmias, nervousness, headache, tremor, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, , hyperglycemia, hypokalemia and metabolic acidosis (serum potassium levels should be monitored) and fatigue. Cardiac arrest and, even, death is associated with the abuse of ASTHALIN Inhaler.
Treatment consists of discontinuation of salbutamol HFA together with appropriate symptomatic therapy. The preferred antidote for overdosage with salbutamol is a cardioselective beta-blocking agent, but beta-blocking drugs should be used with caution in patients with a history of bronchospasm.
If hypokalemia occurs, potassium replacement via the oral route should be given. In patients with severe hypokalemia, intravenous replacement may be necessary. There is insufficient evidence to determine if dialysis is beneficial for overdosage of salbutamol HFA.
ASTHALIN Inhaler …………..Canister containing 200 metered doses
Last Updated: August 2018
Last Reviewed: August 2018